docetaxel anhydrous has been researched along with Hormone-Dependent Neoplasms in 123 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (10.57) | 18.2507 |
| 2000's | 63 (51.22) | 29.6817 |
| 2010's | 47 (38.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohlmann, CH | 1 |
| Carducci, MA; Chen, YH; Cooney, M; Dipaola, R; Dreicer, R; Eisenberger, M; Garcia, JA; Hahn, N; Harshman, LC; Hussain, M; Jarrard, D; Kohli, M; Liu, G; Picus, J; Plimack, ER; Shevrin, D; Sweeney, CJ; Vogelzang, NJ | 1 |
| Carducci, MA; Chen, YH; Cooney, MM; DiPaola, RS; Dreicer, R; Eisenberger, M; Garcia, JA; Hahn, NM; Hussain, M; Jarrard, DF; Kohli, M; Kyriakopoulos, CE; Liu, G; Picus, J; Plimack, ER; Shevrin, DH; Sweeney, CJ; Vogelzang, NJ | 1 |
| Kretschmer, A; Todenhöfer, T | 1 |
| Halabi, S; Parelukar, WR; Rydzewska, L; Tierney, JF; Vale, CL | 1 |
| Lorch, A | 1 |
| Agarwal, N; Carducci, MA; Garzotto, MG; Goldkorn, A; Higano, CS; Hussain, M; Lara, PN; Mack, PC; Moinpour, CM; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, PW; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Iwamura, H; Koie, T; Ohyama, C; Tanaka, T; Tanaka, Y; Tokui, N; Yamamoto, H; Yoneyama, T; Yoshikawa, K | 1 |
| Taneja, SS | 1 |
| Branch, DR; Neschadim, A; Pritzker, KP; Pritzker, LB; Silvertown, JD; Summerlee, AJ; Trachtenberg, J | 1 |
| Atmaca, H; Degirmenci, M; Karaca, B; Kisim, A; Sanli, UA; Sezgin, C; Uslu, R; Uzunoglu, S; Varol, U | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Fiori, C; Porpiglia, F; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Aghai, A; Böttcher, R; Burger, H; de Morrée, ES; de Ridder, CM; de Wit, R; Gibson, AA; Mathijssen, RH; Sparreboom, A; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E | 1 |
| Burich, RA; Holland, WS; Mack, PC; Tepper, C; Vinall, RL; White, RW | 1 |
| Dienes, HP; Engelmann, U; Gerharz, M; Heidenreich, A; Markert, E; Ohlmann, CH; Pfister, D | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| De Santis, M; Fink, E; Hobisch, A; Höltl, W; Krainer, M; Kramer, G; Marei, IC; Neumann, HJ; Rauchenwald, M; Reissigl, A; Schmeller, N; Stackl, W | 1 |
| Donaldson, GW; Moinpour, CM; Nakamura, Y | 1 |
| Bagalà, C; Barone, C; Bianchetti, S; Cassano, A; Fabiano, A; Landriscina, M; Piscazzi, A; Quirino, M; Schinzari, G; Sica, G | 1 |
| Atmaca, H; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S | 1 |
| Economopoulos, T; Floros, T; Gouveris, P; Kamposioras, K; Karageorgopoulou, S; Koumarianou, A; Papatsibas, G; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Tountas, N; Xiros, N | 1 |
| Arima, K; Hasegawa, Y; Kato, M; Kise, H; Nishikawa, K; Soga, N; Sugimura, Y; Yamada, Y | 1 |
| Cuvillier, O; Kohama, T; Nunes, J; Pchejetski, D; Salunkhe, V; Sauer, L; Skalska, L; Waxman, J | 1 |
| Ajarim, DS; Al-Malik, OA; Al-Tweigeri, TA; Alsayed, AA; Alshabanah, MO; El-Husseiny, GA; Elkum, NB; Ezzat, AA; Fatani, DM; Rahal, MM; Tulbah, AM | 1 |
| Bishop, WR; Hsieh, Y; Kirschmeier, P; Liu, G; Long, BJ; Marrinan, CH; Taylor, SA | 1 |
| Gupta, NP; Nayyar, R; Sharma, N | 1 |
| Yuasa, T | 1 |
| Ide, H; Kikuchi, E; Kono, H; Miyajima, A; Nagata, H; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M | 1 |
| Al'bitskiĭ, IA; Fastovets, SV; Gafanov, RA; Kaprin, AD | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, O; Shigemura, K; Yasufuku, T | 1 |
| Beuzeboc, P; Eymard, JC; Ferrero, JM; Gravis, G; Joly, F; Krakowski, I; Oudard, S; Priou, F; Theodore, C; Thill, L; Zannetti, A | 1 |
| Galsky, MD; Vogelzang, NJ | 1 |
| Antonini, N; Linn, SC; Loo, CE; Oldenburg, HS; Rodenhuis, S; Russell, NS; Rutgers, EJ; Straver, ME; Vrancken Peeters, MT; Wesseling, J | 1 |
| Hashine, K; Kusuhara, Y; Miura, N; Numata, K; Shirato, A; Sumiyoshi, Y | 1 |
| Chen, DR; Chen, ST; Hsieh, CM; Huang, CS; Kuo, SH; Lu, YS; Tseng, LM; Wang, HC; Yeh, DC; Yeh, HT | 1 |
| Assayag, F; Berniard, A; Beuzeboc, P; Dahmani, A; de Plater, L; Decaudin, D; Fontaine, JJ; Guyader, C; Marangoni, E; Némati, F; Oudard, S; Pasik, C; Poupon, MF | 1 |
| Dai, B; Shen, YJ; Shi, GH; Yang, LF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Fujisawa, M; Miyake, H; Sakai, I; Terakawa, T | 1 |
| Candeloro, G; Desideri, G; Necozione, S; Piazze, J; Rea, S; Recchia, CO; Recchia, F | 1 |
| Miller, K | 1 |
| Sartor, AO | 1 |
| Biordi, L; Festuccia, C; Gravina, GL; Jannini, EA; Marampon, F; Petini, F; Sherris, D; Tombolini, V | 1 |
| Asmane, I; Barthélémy, P; Bergerat, JP; Céraline, J; Duclos, B; Dufour, P; Kurtz, JE; Litique, V; Rob, L | 1 |
| Efstathiou, E; Hoang, A; Karlou, M; Logothetis, CJ; Pagliaro, LC; Pettaway, CA; Pisters, LL; Troncoso, P; Tzelepi, V; Wen, S | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Amadio, P; Bortolus, R; Caffo, O; Cartenì, G; Facchini, G; Galligioni, E; Gernone, A; Ortega, C; Pagliarulo, V; Prati, V; Re, GL; Sava, T; Veccia, A | 1 |
| Alexandre, J; Bousquet, G; de Mont-Serrat, H; Faivre, S; Goldwasser, F; Kaiser, R; Le Tourneau, C; Misset, JL; Raymond, E | 1 |
| Braeckman, J; Decoster, L; Degrève, J; Fontaine, C; Schallier, D | 1 |
| Akaza, H; Arai, Y; Fujita, R; Hashine, K; Hoshi, S; Kakehi, Y; Kanayama, HO; Miki, T; Miura, T; Mizokami, A; Nishimura, K; Nonomura, K; Nonomura, N; Ogawa, O; Ozono, S | 1 |
| Akseli, H; Claes, G; Ginman, C; Harmenberg, U; Heikkinen, M; Hemminki, A; Hervonen, P; Igor, Z; Ilari, L; Joensuu, H; Joensuu, T; Kellokumpu-Lehtinen, PL; Lehtinen, I; Luukkaa, M; Luukkaala, T; Marjaanai, L; McDermott, R; Mirja, H; Nilsson, S; Nyandoto, P; Paul, N; Pirkko-Liisa, KL; Ray, M; Sten, N; Tiina, L; Ulrika, H; Zaitsev, I | 1 |
| Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S | 1 |
| McKeage, K | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Clarke, NW | 1 |
| Cheng, HH; Lin, DW; Yu, EY | 1 |
| Antonarakis, ES; Eisenberger, MA | 1 |
| Lewis, B; Pal, SK; Sartor, O | 1 |
| Yu, EY; Zhao, S | 1 |
| Araujo, JC; Chatterji, T; Dayyani, F; Gallick, GE; Logothetis, CJ; Song, JH; Trudel, GC; Varkaris, A | 1 |
| Saylor, PJ | 1 |
| Nishimura, K; Nonomura, N; Okuyama, A; Takahara, S | 1 |
| Davis, TL; Hauke, R; Kakitelashvilli, V; Kellerman, M; Lee, MS; Lin, MF; Lugo, E; Spellman, M; Taylor, R; Zelivianski, S; Zhou, XW | 1 |
| Godley, PA; Halabi, S; Kelly, WK; Oh, WK; Small, EJ; Vogelzang, NJ; Werner, C | 1 |
| Beer, TM; Eilers, KM; Garzotto, M; Henner, WD; Wersinger, EM | 1 |
| Debes, JD; Tindall, DJ | 1 |
| Hisatake, Y; Ikezoe, T; Koeffler, HP; Ohtsuki, Y; Said, JW; Taguchi, H; Takeuchi, T; Yang, Y | 1 |
| Dandekar, DS; Lokeshwar, BL | 1 |
| Abraham, S; Dagher, R; Li, N; Pazdur, R; Rahman, A; Sridhara, R | 1 |
| Itoh, N | 1 |
| Kubota, Y; Miyoshi, Y; Uemura, H | 1 |
| Abraham, S; Capanna, T; DiPaola, RS; Doyle-Lindrud, S; Goodin, S; Medina, P; Shih, WJ; Todd, M; Winnie, J | 1 |
| Andrieu, JM; Banu, A; Banu, E; Beuzeboc, P; Coscas, Y; Dourthe, LM; Guinet, F; Hardy-Bessard, AC; Linassier, C; Oudard, S; Poupon, MF; Scotté, F; Voog, E | 1 |
| Doggrell, SA | 1 |
| Arena, G; Bertelli, G; Botto, A; Colantonio, I; Fea, E; Garrone, O; Giubergia, S; Heouaine, A; Merlano, M; Occelli, M | 1 |
| Beer, TM; Garzotto, M; Ryan, CW; Tiffany, NM; Wersinger, EM | 1 |
| Boyer, MJ; Clarke, S; Joshua, AM; Nordman, I; Stockler, MR; Venkataswaran, R | 1 |
| Keam, SJ; McKeage, K | 1 |
| Banu, E; Medioni, J; Oudard, S; Scotté, F | 1 |
| Bonhoure, E; Calvet, C; Cuvillier, O; Doumerc, N; Garcia, V; Golzio, M; Malavaud, B; Mazerolles, C; Pchejetski, D; Rischmann, P; Teissié, J | 1 |
| Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G | 1 |
| Ankerst, DP; Benson, MC; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, JA; Kohli, M; Lara, PN; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME | 1 |
| Ando, J; Asaga, T; Fujii, H; Inoue, K; Kimura, M; Kurosumi, M; Sano, M; Sato, N; Tabei, T; Yamamoto, N | 1 |
| Cavaglione, G; Chamorey, E; Dides, S; Ferrero, JM; Foa, C; Kaphan, R; Lesbats, G; Nouyrigat, P; Oudard, S | 1 |
| Asmar, L; Boehm, KA; Ilegbodu, D; Kolodziej, M; Mull, S; Neubauer, MA; Perrine, G; Pluenneke, RE; Rousey, SR | 1 |
| Mancuso, A; Oudard, S; Sternberg, CN | 1 |
| Asmar, L; Berry, W; Boehm, KA; Chittoor, S; Fleagle, J; Loesch, D; Logie, K; Mull, S; Zhan, F | 1 |
| Agus, D; Dreicer, R; Petrylak, D; Roth, B; Webb, I | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Vankatraman, G | 1 |
| Beke, D; Kudlacek, S; Meran, JG | 1 |
| Bertelli, G; Jones, RM; Leonard, RC; Lewis, PD; Morgan, C; Thomas, GA | 1 |
| Gross, M; Hussain, MH; Hutcheon, D; Kelly, WK; Michaelson, D; Rosenberg, JE; Small, EJ; Weinberg, VK; Wilding, G | 1 |
| Etienne-Grimaldi, MC; Ferrero, JM; Fischel, JL; Formento, P; Guérin, O; Hofman, P; Lo Nigro, C; Merlano, M; Milano, G | 1 |
| Daskivich, TJ; Oh, WK; Regan, MM | 1 |
| Alfaro, J; Carles, J; Catalan, G; Domenech, M; Font, A; Gallardo, E; Gonzalez Del Alba, A; González-Larriba, JL; Lianes, P; Mellado, B; Nogué, M; Tello, JM | 1 |
| Jacobus, S; Kantoff, PW; McKearn, D; Nakabayashi, M; Oh, WK; Regan, MM; Ross, RW; Sartor, O; Taplin, ME | 1 |
| Andersen, RJ; Ettinger, S; Gleave, ME; Hadaschik, BA; Roberge, M; Sowery, RD; Zoubeidi, A | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C | 1 |
| de Wit, R | 1 |
| Chaladaj, A; Droz, JP | 1 |
| Fazli, L; Gleave, ME; Hadaschik, BA; Hurtado-Coll, A; So, AI; Sowery, RD; Zoubeidi, A | 1 |
| Beer, TM; Chi, KN; Curd, JG; Eilers, KM; Henner, WD; Lalani, AS; Lee, S; Mori, M; Ruether, JD; Ryan, CW; Venner, P | 1 |
| de Wit, R; Hamberg, P; Verhagen, PC | 1 |
| Nabhan, C | 1 |
| Fischel, JL; Formento, P; Lo Nigro, C; Maffi, M; Merlano, M; Milano, G | 1 |
| Vogelzang, NJ | 1 |
| Stein, CA | 1 |
| Earhart, RH | 1 |
| Picus, J; Schultz, M | 1 |
| Cohen, J; Dimitt, B; Friedland, D; Gluckman, R; Keating, M; Lembersky, B; Miller, R; Reilly, N; Voloshin, M; Zidar, B | 1 |
| Bagiella, E; Benson, M; England-Owen, C; Hetjan, D; Judge, T; Macarthur, R; Newhouse, J; O'Connor, J; Olsson, C; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Weitzman, A; Zuech, N | 1 |
| Budman, D; Kreis, W | 1 |
| Halabi, S; Hars, V; Kreis, W; Savarese, D; Taplin, ME; Vogelzang, N | 1 |
| Carducci, M; Eisenberger, M; Laufer, M; Sinibaldi, VJ | 1 |
| Kantoff, PW; Oh, WK | 1 |
| Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C | 1 |
| Reese, DM; Small, EJ; Vogelzang, NJ | 1 |
| Kamradt, JM; Korenchuk, S; Muenchen, HJ; Pienta, KJ; Williams, JF | 1 |
| Heicappell, R | 1 |
30 review(s) available for docetaxel anhydrous and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
[Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
Topics: Androgen Antagonists; Combined Modality Therapy; Disease Progression; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2017 |
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
[Metastatic prostate cancer: new insights and developments].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Denosumab; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Taxoids | 2013 |
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Odds Ratio; Prostatic Neoplasms; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
Docetaxel-based combination therapy for castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids | 2010 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts | 2011 |
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Treatment Outcome | 2011 |
New strategies for medical management of castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids | 2011 |
Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Male; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Orchiectomy; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2012 |
Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Design; Endothelin Receptor Antagonists; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Research; Taxoids; Treatment Outcome | 2012 |
Advanced clinical states in prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Cancer Vaccines; Disease Progression; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Failure | 2012 |
Prostate cancer: The androgen receptor remains front and centre.
Topics: Abiraterone Acetate; Adenocarcinoma; Androgen Antagonists; Androgens; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Enzyme Inhibitors; Humans; Male; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Survival Rate; Taxoids | 2013 |
[Therapy for hormone-refractory prostate cancer].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Cyclophosphamide; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids; Tegafur; Treatment Outcome | 2002 |
[Chemotherapy for prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bridged-Ring Compounds; Docetaxel; Drug Resistance; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2005 |
[Treatment of androgen-independent hormone refractory prostate cancer using docetaxel].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dexamethasone; Docetaxel; Estramustine; Gene Silencing; Genes, bcl-2; Humans; Male; Microtubules; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Which drug combination for hormone-refractory prostate cancer?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids | 2005 |
Docetaxel in hormone-refractory metastatic prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids | 2005 |
[Prostate cancer: update].
Topics: Androgen Antagonists; Antineoplastic Agents; Cancer Vaccines; Clinical Trials, Phase III as Topic; Docetaxel; Extracellular Signal-Regulated MAP Kinases; Humans; Male; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Radiotherapy; Receptor, ErbB-2; Taxoids | 2005 |
Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Epothilones; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 2007 |
[The hormone refractory prostate cancer - a challenge for the internal specialist].
Topics: Androgen Antagonists; Antineoplastic Agents; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Internal Medicine; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2007 |
Chemotherapy in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Multivariate Analysis; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nomograms; Predictive Value of Tests; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids | 2008 |
Management of metastatic prostate cancer: the crucial role of geriatric assessment.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Geriatric Assessment; Humans; Lymphatic Metastasis; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2008 |
When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
Topics: Antineoplastic Agents, Hormonal; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Nomograms; Prostatic Neoplasms; Taxoids | 2008 |
Mechanisms of action of taxanes in prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Microtubules; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Suppressor Protein p53 | 1999 |
Docetaxel (Taxotere): preclinical and general clinical information.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Hormone-refractory prostate cancer: an evolving standard of care.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Taxoids; Testosterone; Treatment Outcome | 2002 |
40 trial(s) available for docetaxel anhydrous and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2018 |
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Survival Rate; Taxoids | 2013 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Models, Statistical; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2009 |
Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Doxorubicin; Estrogens; Female; Genes, erbB-2; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Progesterone; Prospective Studies; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Treatment Outcome; Young Adult | 2010 |
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
[Combined treatment of metastatic hormone-resistant prostate cancer].
Topics: Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasms, Hormone-Dependent; Palliative Care; Prednisolone; Prostatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2010 |
Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasms, Hormone-Dependent; Prednisolone; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Prospective Studies; Taxoids | 2011 |
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Topics: Adenocarcinoma; Adult; Aged; Androgens; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Adhesion Molecules; Combined Modality Therapy; Cystectomy; Disease Progression; Docetaxel; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neoplastic Stem Cells; Neovascularization, Physiologic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Signal Transduction; Taxoids; Time Factors | 2011 |
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.
Topics: Administration, Oral; Aged; Antigens; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids | 2011 |
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prednisolone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids | 2012 |
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Niacinamide; Orchiectomy; Phenylurea Compounds; Pilot Projects; Prednisone; Prospective Studies; Prostatic Neoplasms; Pyridines; Sorafenib; Taxoids; Testosterone | 2012 |
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Estramustine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Approval; Drug Interactions; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; United States; United States Food and Drug Administration | 2004 |
Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Estramustine; Gefitinib; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids | 2006 |
Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Respiratory Tract Neoplasms; Risk Assessment; Skin Neoplasms; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome | 2006 |
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Dose-Response Relationship, Drug; Humans; Interleukin-6; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Taxoids | 2007 |
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Taxoids | 2007 |
Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Proliferation; Docetaxel; Flow Cytometry; Gene Expression Profiling; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Oligopeptides; Prostatic Neoplasms; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Topics: Androgens; Cell Line, Tumor; Clusterin; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Humans; Immunohistochemistry; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Prostatectomy; Prostatic Neoplasms; Taxoids; Thionucleotides | 2008 |
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Calcitriol; Calcium Channel Agonists; Docetaxel; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Placebos; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2008 |
Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 1999 |
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Gene Expression; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids | 1999 |
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
53 other study(ies) available for docetaxel anhydrous and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tubulin Modulators | 2019 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles | 2013 |
A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy, Needle; Bone Neoplasms; Diagnostic Imaging; Disseminated Intravascular Coagulation; Docetaxel; Drug Resistance, Neoplasm; False Negative Reactions; Fatal Outcome; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Unknown Primary; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Transurethral Resection of Prostate | 2014 |
Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2014 |
Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding, Competitive; Blotting, Western; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Receptors, G-Protein-Coupled; Receptors, Peptide; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2015 |
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Topics: Adenocarcinoma; Androgens; Androstenes; Animals; Antineoplastic Agents, Phytogenic; Benzamides; Biological Transport; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterografts; Humans; Male; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Organic Anion Transporters, Sodium-Independent; Phenylthiohydantoin; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2016 |
Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Genistein; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Pyrimidines; src-Family Kinases; Taxoids; Tosyl Compounds | 2008 |
[Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Biomarkers, Tumor; Biopsy; Cetuximab; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Lymph Nodes; Male; Neoplasms, Hormone-Dependent; Piperazines; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Androgen; Taxoids; Trastuzumab | 2008 |
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Diphosphonates; Docetaxel; Drug Synergism; Enzyme Activation; Fluorescent Dyes; Humans; Imidazoles; In Situ Nick-End Labeling; Male; MAP Kinase Kinase 1; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Taxoids; Time Factors; Zoledronic Acid | 2008 |
[Chemotherapy for prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Palliative Care; Patient Care Team; Prostatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Dihydrotestosterone; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nevirapine; Nitriles; Prostatic Neoplasms; Random Allocation; Receptors, Androgen; Reverse Transcriptase Inhibitors; RNA, Neoplasm; Signal Transduction; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays | 2009 |
Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Intercellular Signaling Peptides and Proteins; Male; Neoplasms, Hormone-Dependent; Octreotide; Prostate; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2009 |
Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Taxoids | 2009 |
Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Male; Neoplasms, Hormone-Dependent; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Taxoids | 2009 |
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Hormone-Dependent; Piperidines; Prostatic Neoplasms; Pyridines; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Neoplasms, Hormone-Dependent; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2010 |
Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2010 |
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2010 |
A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
Topics: Aged; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Docetaxel; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Estramustine; Gastrointestinal Diseases; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Vascular Diseases; Venous Thrombosis; Xenograft Model Antitumor Assays | 2010 |
Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; MicroRNAs; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2011 |
Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Taxoids; Tumor Cells, Cultured | 2011 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Estriol; Estrogen Antagonists; Female; Humans; Ifosfamide; Leuprolide; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triazoles; Tumor Necrosis Factor Ligand Superfamily Member 15 | 2011 |
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzopyrans; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Taxoids; Transcription Factors | 2011 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; Docetaxel; Follow-Up Studies; Humans; Male; Meningeal Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Drug Administration Schedule; Humans; Male; Methylprednisolone; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Novel and bone-targeted agents for CRPC.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Ipilimumab; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts; Tumor Microenvironment | 2012 |
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cytotoxins; Disease Progression; Docetaxel; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Castrate-resistant prostate cancer: postdocetaxel management.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Design; Drug Resistance, Neoplasm; Immunotherapy; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Insulin-Like Growth Factor I; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Osteoblasts; Prostatic Neoplasms; Pyrimidines; Taxoids; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.
Topics: Apoptosis; bcl-X Protein; Butadienes; Docetaxel; Drug Synergism; Enzyme Inhibitors; Flavonoids; Humans; Male; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2003 |
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Disease-Free Survival; Docetaxel; Feasibility Studies; Humans; Lymphatic Metastasis; Male; Neoplasms, Hormone-Dependent; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2004 |
Mechanisms of androgen-refractory prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Resistance, Neoplasm; Gene Amplification; Humans; Male; Mutation; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Taxoids | 2004 |
HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Neoplasm; Docetaxel; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Ritonavir; RNA, Messenger; RNA, Small Interfering; Taxoids; Xenograft Model Antitumor Assays | 2004 |
Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA, Complementary; Docetaxel; Drug Therapy, Combination; Gene Expression Regulation, Enzymologic; Male; Mice; Microcirculation; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tetracycline; Tumor Cells, Cultured | 2004 |
[Docetaxel--standard therapy further optimized].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cholecalciferol; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
[Longer life in hormone refractory prostatic carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Survival Rate; Taxoids | 2005 |
Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Ceramides; Disease Models, Animal; Docetaxel; Flow Cytometry; Green Fluorescent Proteins; Humans; Lysophospholipids; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; RNA Interference; Sphingosine; Taxoids; Tumor Cells, Cultured | 2005 |
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Predictive Value of Tests; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Taxoids; Time Factors | 2006 |
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cytochromes c; Docetaxel; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Immunohistochemistry; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Taxoids; Tumor Cells, Cultured; Veratrum Alkaloids | 2007 |
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Minichromosome Maintenance Complex Component 2; Neoplasms, Hormone-Dependent; Nuclear Proteins; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Docetaxel; Gene Expression Profiling; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Time Factors | 2007 |
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2008 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Monitoring; Estrogens; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Progesterone; Prognosis; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Is chemotherapy the standard for asymptomatic androgen-independent prostate cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2008 |
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Docetaxel; Drug Evaluation; Drug Resistance, Neoplasm; Humans; Male; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Hormone-Dependent; Peptides, Cyclic; Prostatic Neoplasms; Signal Transduction; Somatostatin; Taxoids | 2008 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Docetaxel (Taxotere): a new option for the treatment of hormone-refractory prostate cancer. Proceedings of a symposium. Chicago, Illinois, USA. April 23, 1999.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Estramustine; Humans; Inhibitory Concentration 50; Male; Microtubules; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Taxoids; Tumor Cells, Cultured | 2000 |